National health security starts with a factory, not a stockpile

The last decade taught every health ministry in the region the same lesson twice: when global supply tightens, contracts matter less than proximity.

Stockpiling is the intuitive response, and it is a poor one. Inventory expires, ties up capital, and covers only the molecules someone thought to buy. It does nothing for a therapy that becomes essential after the purchase order was written.

Manufacturing capability behaves differently. A facility with licensed lines, trained staff and a live regulatory relationship can be redirected. It can add a molecule, scale a format, or absorb a technology transfer in months rather than years.

This is the reasoning behind the group's position in Egyptian pharmaceutical manufacturing. A complex producing 280 million units annually across fourteen dosage formats is not primarily a commercial asset — it is regional supply infrastructure that happens to be commercially viable.